More good news from vaccine firm Acambis in Fulbourn Road.
Shot in arm for Acambis
It has just started the next phase of clinical trials on its vaccine against Japanese encephalitis (JE).
Boss, John Brown says: 'With an estimated three billion people a year at risk from JE across Asia and Australia, this is an important new vaccine we are developing.
'We are delighted that our project is proceeding on schedule and expect the results to be available around the end of 2001.'
Potential market for the Acambis JE vaccine is estimated at $300 a year, with the wider diseases the basic vaccine targets looking at a $1 billion annual market. The share price lifted 4.5p to 128p.